

---

---

# SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

---

## FORM 8-K

---

**CURRENT REPORT**  
**Under Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):**  
**June 28, 2022**

---

### ResMed Inc.

(Exact Name of Registrant as Specified in Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-15317**  
(Commission  
File Number)

**98-0152841**  
(I.R.S. Employer  
Identification No.)

**9001 Spectrum Center Blvd.**  
**San Diego, California 92123**  
(Address of Principal Executive Offices)

**(858) 836-5000**  
(Registrant's telephone number, including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.004 par value	RMD	NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

---

---

---

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On June 28, 2022, we announced that we are promoting Lucile Blaise, age 51, to serve as our president, sleep and respiratory care business. The promotion is effective July 1, 2022. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K.

Ms. Blaise, previously ResMed's vice president of sleep & respiratory care for Western Europe, is a medtech industry thought leader with over 25 years' experience in medical device sales, marketing, finance, and business development.

Since June 2015, Ms. Blaise has served as ResMed's vice president of sleep & respiratory care for Western Europe. From September 2012 to June 2015, she served as ResMed's vice president, France and North Africa. From November 2019 to September 2012, she served as marketing director - France, and from November 2006 to November 2009, she served as ventilation product manager for ResMed. Before that, she held sales and marketing positions with medical device companies Weinman France, Thuasne, and Tyco Healthcare.

Ms. Blaise has served for 6 years on the board of National Union of the Medical Technology Industry (Snitem), a professional organization representing medical device companies operating in France, and was elected its president in June 2022. Since 2020, she has also served on the board of MedTech Europe, the European trade association for the medical technology industry including diagnostics, medical devices and digital health.

In connection with the promotion, and effective July 1, 2022, we made the following compensation arrangements with Ms. Blaise: she will receive an annual base salary of \$470,000, with a target short-term incentive opportunity of 80%, and an equity award with a target value of \$1,400,000. These elements are structured materially consistent with the executive compensation programs for executive officers, as disclosed in our proxy statement on Schedule 14A, filed with the SEC on October 6, 2021. We will provide relocation benefits in connection with her expected move to the United States consistent with our mobility policy. We also expect to enter into an executive agreement providing change of control benefits, materially consistent with the change of control agreements described in the same Schedule 14A.

There is no arrangement or understanding with any other person pursuant to which Ms. Blaise was appointed to serve as our president, sleep and respiratory care business, and there are no family relationships between Ms. Blaise and any director or executive officer of ResMed that are required to be disclosed under Item 401(d) of Regulation S-K. Additionally, there are no transactions between ResMed and Ms. Blaise that would require disclosure under Item 404(a) of Regulation S-K.

Concurrent with Ms. Blaise's July 1, 2022 appointment, Robert Douglas will no longer serve as our interim president, sleep and respiratory care business. He will continue as our president and chief operating officer.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

99.1 [Press release issued by ResMed Inc. on June 28, 2022.](#)

104 Cover Page Interactive Data File (embedded within the inline XBRL document).

---

## SIGNATURES

We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

Date: July 1, 2022

**RESMED INC.**  
(registrant)

By: /s/ David Pendarvis

Name: David Pendarvis

Its: Chief administrative officer, global general  
counsel and secretary

**For media**

Jayne Rubenstein  
 +1 858.836.6798  
[news@resmed.com](mailto:news@resmed.com)

**For investors**

Amy Wakeham  
 +1 858.836.5000  
[investorrelations@resmed.com](mailto:investorrelations@resmed.com)

**ResMed Promotes Lucile Blaise to President, Sleep & Respiratory Care**

- *Blaise is a medtech industry thought leader with over 25 years' experience*
- *A board member of MedTech Europe since 2020; President of the Snitem, France's premier medtech association*
- *Promotion effective July 1*

SAN DIEGO, June 28, 2022 – ResMed (NYSE: RMD, ASX: RMD) today announced the promotion of Lucile Blaise to President of Sleep & Respiratory Care, effective July 1, 2022.

Blaise, currently ResMed's Vice President of Sleep & Respiratory Care for Western Europe, is a medtech industry thought leader with over 25 years' experience in medical device sales, marketing, finance, and business development. With ResMed since 2006, she has led her team's efforts with industry and public partners to establish payer market access and reimbursements for digital health telemonitoring in France and Belgium, is an outspoken advocate for real-world evidence and applying it to value-based healthcare systems. Blaise is also dedicated to maintaining patient data privacy and security, as ResMed and other healthcare leaders liberate data and unlock value for patients, physicians, and providers, to lower costs and improve health outcomes.

Blaise has served for 6 years on the board of Snitem, France's premier medtech association, and was elected its president in June 2022. She has also served on the board of MedTech Europe since 2020.

"I'm thrilled that Lucile – one of Europe's leading champions of digital health innovation and adoption, as well as data privacy and security – has accepted this promotion to lead ResMed's global Sleep & Respiratory Care business," said ResMed CEO Mick Farrell. "Throughout her 16 years at ResMed and over 25 years in the medtech industry, Lucile has been a key player in improving chronic disease treatment for millions of people with sleep apnea and respiratory insufficiency, as well as supporting physicians, providers, and healthcare systems across Europe, and beyond, through evidence-based decision making. Lucile is committed to collaboration across the company, and the industry, and always places the needs of the patient first. She exemplifies the deep bench of innovative, accomplished leaders across ResMed, bringing in-depth market knowledge, customer insight, and commercial skills to our CEO operations leadership team, as together we continue to transform our business and the market through digital health."

---

## About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit [ResMed.com](https://www.resmed.com) and follow [@ResMed](https://twitter.com/ResMed)

###